W., Rasmussen, S., Hansen, M
Independently verified Tested by an accredited US third-party lab for identity, purity, and concentration
Shortage of diabetes, weight-loss drug Ozempic expected in Canada, says manufacturer Novo Nordisk says it is experiencing a temporary supply disruption with an injection pen A shortage of diabetes drug Ozempic that is used off-label for weight loss is expected in Canada, manufacturer Novo Nordisk and Health Canada said on Friday
Key preclinical findings included: Dose-dependent weight loss exceeding that of single- or dual-receptor agonists Improved glucose tolerance and insulin sensitivity Increased energy expenditure attributable to the glucagon receptor component Reduced hepatic steatosis Acceptable preclinical safety and toxicology profile These data supported an Investigational New Drug (IND) application to the FDA, enabling the transition to human clinical testing
Learn more about the legal landscape here
The burden now for paying for weight loss treatments typically falls to the patient
